Share Price and Basic Stock Data
Last Updated: January 19, 2026, 1:49 pm
| PEG Ratio | 2.23 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Beryl Drugs Ltd operates within the pharmaceutical sector, focusing on the production and distribution of various drug formulations. The company reported a market capitalization of ₹11.3 Cr, with its stock priced at ₹22.2. The revenue trajectory has shown fluctuations, with sales of ₹26.84 Cr for the fiscal year ending March 2023, slightly declining to ₹26.73 Cr in FY 2024, and further projected to be ₹21.15 Cr in FY 2025. Quarterly sales figures indicate variability, with the highest sales of ₹8.19 Cr recorded in December 2022, while the lowest was ₹3.21 Cr in March 2024. Analyzing the quarterly performance, the company faced a dip in sales in March 2023, which may reflect seasonal trends or operational challenges. The overall sales growth from ₹14.48 Cr in FY 2022 to ₹26.84 Cr in FY 2023 demonstrates a significant recovery, indicating a potential rebound in demand for pharmaceutical products post-pandemic.
Profitability and Efficiency Metrics
Beryl Drugs Ltd’s profitability metrics reveal a mixed performance, with a reported net profit of ₹0.23 Cr and a P/E ratio of 49.0, suggesting a high valuation relative to earnings. The operating profit margin (OPM) stood at 14.15%, reflecting a solid operational efficiency relative to industry standards. However, the company has faced challenges, as evidenced by the fluctuating net profits over recent quarters, including a loss of ₹0.35 Cr in March 2024. The operating profit for FY 2023 was ₹2.00 Cr, which declined to ₹1.24 Cr for FY 2025, highlighting potential cost control issues. The interest coverage ratio (ICR) of 10.28x indicates that Beryl Drugs can comfortably meet its interest obligations, although the cash conversion cycle (CCC) of 94.23 days suggests room for improvement in working capital management. This efficiency metric points towards a need for better inventory and receivables management to enhance profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Beryl Drugs Ltd shows a total asset value of ₹15.96 Cr and total borrowings of ₹4.30 Cr as of September 2025, indicating a manageable debt level relative to its asset base. The company’s reserves increased to ₹4.37 Cr, reflecting a strengthening of equity capital, which has remained stable at ₹5.09 Cr since FY 2014. The return on equity (ROE) stood at 6.30%, which is lower than the industry average, indicating that while equity is being utilized, the returns generated are modest. Furthermore, the debt-to-equity ratio appears to be favorable, suggesting a conservative approach to leveraging. However, the decline in net profit from ₹0.77 Cr in FY 2023 to ₹0.58 Cr in FY 2025 raises concerns about future profitability. The company has maintained a consistent interest coverage ratio, reinforcing its capability to service debt, but further analysis is warranted to assess long-term financial stability.
Shareholding Pattern and Investor Confidence
Beryl Drugs Ltd’s shareholding pattern reveals that promoters hold 26.38% of the equity, while the public holds a significant 73.62%. The number of shareholders has increased to 7,446, indicating growing public interest and confidence in the company’s prospects. The stability in promoter holding suggests no recent dilution of ownership, which can be perceived as a positive signal for investors. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests that institutional confidence may be lacking, potentially limiting the stock’s liquidity and upward momentum. The shareholding stability over recent quarters, where promoter and public ownership percentages have remained consistent, may provide a sense of security for retail investors. However, the absence of institutional backing could raise concerns about the stock’s long-term appeal among larger investors.
Outlook, Risks, and Final Insight
The outlook for Beryl Drugs Ltd appears cautiously optimistic, contingent upon its ability to stabilize revenue streams and enhance profitability. Key strengths include a manageable debt profile, a solid interest coverage ratio, and a stable shareholder base. However, risks persist, notably the declining net profits and fluctuating quarterly sales, which could impact investor sentiment. Additionally, the company’s reliance on a predominantly retail shareholder base poses a risk if market conditions change. To bolster its position, Beryl Drugs must focus on improving operational efficiencies and managing costs effectively. If the company can leverage its existing strengths and navigate the outlined risks, it could enhance its market presence and financial performance. Conversely, failure to address these issues may hinder growth prospects and investor confidence in the long term.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,884 Cr. | 356 | 479/192 | 80.4 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,919.18 Cr | 1,108.93 | 52.11 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.90 | 8.19 | 6.09 | 8.18 | 8.09 | 7.66 | 3.21 | 6.29 | 5.64 | 5.40 | 5.22 | 4.83 | 5.16 |
| Expenses | 7.27 | 7.47 | 5.82 | 7.05 | 7.37 | 6.87 | 3.19 | 5.30 | 5.08 | 4.81 | 4.72 | 4.28 | 4.43 |
| Operating Profit | 0.63 | 0.72 | 0.27 | 1.13 | 0.72 | 0.79 | 0.02 | 0.99 | 0.56 | 0.59 | 0.50 | 0.55 | 0.73 |
| OPM % | 7.97% | 8.79% | 4.43% | 13.81% | 8.90% | 10.31% | 0.62% | 15.74% | 9.93% | 10.93% | 9.58% | 11.39% | 14.15% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.11 | 0.12 | 0.06 | 0.12 | 0.10 | 0.11 | 0.13 | 0.21 | 0.12 | 0.12 | 0.08 | 0.10 | 0.08 |
| Depreciation | 0.19 | 0.22 | 0.15 | 0.28 | 0.29 | 0.31 | 0.32 | 0.28 | 0.33 | 0.31 | 0.32 | 0.38 | 0.39 |
| Profit before tax | 0.33 | 0.38 | 0.06 | 0.73 | 0.33 | 0.37 | -0.43 | 0.50 | 0.11 | 0.16 | 0.10 | 0.07 | 0.26 |
| Tax % | -6.06% | 60.53% | -16.67% | 27.40% | 18.18% | 16.22% | -16.28% | 26.00% | 90.91% | 62.50% | -50.00% | 71.43% | 96.15% |
| Net Profit | 0.34 | 0.14 | 0.06 | 0.53 | 0.27 | 0.31 | -0.35 | 0.37 | 0.01 | 0.05 | 0.15 | 0.02 | 0.01 |
| EPS in Rs | 0.67 | 0.28 | 0.12 | 1.05 | 0.53 | 0.61 | -0.69 | 0.73 | 0.02 | 0.10 | 0.30 | 0.04 | 0.02 |
Last Updated: December 27, 2025, 8:40 pm
Below is a detailed analysis of the quarterly data for Beryl Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 5.16 Cr.. The value appears strong and on an upward trend. It has increased from 4.83 Cr. (Jun 2025) to 5.16 Cr., marking an increase of 0.33 Cr..
- For Expenses, as of Sep 2025, the value is 4.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.28 Cr. (Jun 2025) to 4.43 Cr., marking an increase of 0.15 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.73 Cr.. The value appears strong and on an upward trend. It has increased from 0.55 Cr. (Jun 2025) to 0.73 Cr., marking an increase of 0.18 Cr..
- For OPM %, as of Sep 2025, the value is 14.15%. The value appears strong and on an upward trend. It has increased from 11.39% (Jun 2025) to 14.15%, marking an increase of 2.76%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.10 Cr. (Jun 2025) to 0.08 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.38 Cr. (Jun 2025) to 0.39 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Jun 2025) to 0.26 Cr., marking an increase of 0.19 Cr..
- For Tax %, as of Sep 2025, the value is 96.15%. The value appears to be increasing, which may not be favorable. It has increased from 71.43% (Jun 2025) to 96.15%, marking an increase of 24.72%.
- For Net Profit, as of Sep 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.02 Cr. (Jun 2025) to 0.01 Cr., marking a decrease of 0.01 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.02. The value appears to be declining and may need further review. It has decreased from 0.04 (Jun 2025) to 0.02, marking a decrease of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:05 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14.54 | 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.73 | 21.15 | 20.61 |
| Expenses | 13.77 | 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.45 | 19.91 | 18.24 |
| Operating Profit | 0.77 | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.28 | 1.24 | 2.37 |
| OPM % | 5.30% | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.53% | 5.86% | 11.50% |
| Other Income | 0.18 | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.40 | 1.41 | 0.00 |
| Interest | 0.20 | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.47 | 0.54 | 0.38 |
| Depreciation | 0.32 | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.25 | 1.40 |
| Profit before tax | 0.43 | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 | 0.86 | 0.59 |
| Tax % | 37.21% | 38.46% | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% | 33.72% | |
| Net Profit | 0.27 | 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.58 | 0.23 |
| EPS in Rs | 0.53 | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 1.14 | 0.46 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -70.37% | 112.50% | -364.71% | 320.00% | -40.40% | -91.53% | 380.00% | -375.00% | 216.67% | 0.00% | -24.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | 182.87% | -477.21% | 684.71% | -360.40% | -51.12% | 471.53% | -755.00% | 591.67% | -216.67% | -24.68% |
Beryl Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 16% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 63% |
| 3 Years: | 42% |
| TTM: | -62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 29% |
| 3 Years: | 35% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 3% |
| 3 Years: | 8% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: December 10, 2025, 3:56 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves | 1.33 | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.41 | 4.37 |
| Borrowings | 1.53 | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.07 | 4.30 |
| Other Liabilities | 1.79 | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 2.39 | 3.65 |
| Total Liabilities | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 | 17.41 |
| Fixed Assets | 2.79 | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 6.20 | 7.62 |
| CWIP | 0.13 | 0.24 | 0.00 | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.83 |
| Investments | 0.73 | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.00 | 0.00 | 0.00 |
| Other Assets | 6.09 | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.76 | 8.96 |
| Total Assets | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 | 17.41 |
Below is a detailed analysis of the balance sheet data for Beryl Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.09 Cr..
- For Reserves, as of Sep 2025, the value is 4.37 Cr.. The value appears to be declining and may need further review. It has decreased from 4.41 Cr. (Mar 2025) to 4.37 Cr., marking a decrease of 0.04 Cr..
- For Borrowings, as of Sep 2025, the value is 4.30 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 4.07 Cr. (Mar 2025) to 4.30 Cr., marking an increase of 0.23 Cr..
- For Other Liabilities, as of Sep 2025, the value is 3.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.39 Cr. (Mar 2025) to 3.65 Cr., marking an increase of 1.26 Cr..
- For Total Liabilities, as of Sep 2025, the value is 17.41 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.96 Cr. (Mar 2025) to 17.41 Cr., marking an increase of 1.45 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7.62 Cr.. The value appears strong and on an upward trend. It has increased from 6.20 Cr. (Mar 2025) to 7.62 Cr., marking an increase of 1.42 Cr..
- For CWIP, as of Sep 2025, the value is 0.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.83 Cr., marking an increase of 0.83 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 8.96 Cr.. The value appears to be declining and may need further review. It has decreased from 9.76 Cr. (Mar 2025) to 8.96 Cr., marking a decrease of 0.80 Cr..
- For Total Assets, as of Sep 2025, the value is 17.41 Cr.. The value appears strong and on an upward trend. It has increased from 15.96 Cr. (Mar 2025) to 17.41 Cr., marking an increase of 1.45 Cr..
Notably, the Reserves (4.37 Cr.) exceed the Borrowings (4.30 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.76 | -0.99 | -1.19 | -1.78 | -0.44 | -2.22 | -4.32 | -3.67 | -4.85 | -2.54 | -2.81 | -2.83 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64.26 | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.51 | 94.23 |
| Inventory Days | 52.84 | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | |||
| Days Payable | 50.59 | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | |||
| Cash Conversion Cycle | 66.51 | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.51 | 94.23 |
| Working Capital Days | 36.90 | 38.35 | 58.44 | 67.31 | 71.89 | -6.55 | 13.99 | 38.76 | 63.52 | 46.51 | 57.90 | 68.00 |
| ROCE % | 8.42% | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.05% | 10.15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 18 | Mar 17 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.96 | 0.00 |
| Diluted EPS (Rs.) | 1.96 | 0.00 |
| PBDIT Margin (%) | 10.56 | 1.89 |
| PBIT Margin (%) | 8.50 | -1.38 |
| PBT Margin (%) | 7.67 | -3.12 |
| Net Profit Margin (%) | 6.21 | -3.59 |
| NP After MI And SOA Margin (%) | 6.21 | -3.59 |
| Interest Coverage Ratio (X) | 10.28 | -0.79 |
| Interest Coverage Ratio (Post Tax) (X) | 8.50 | -1.06 |
After reviewing the key financial ratios for Beryl Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 17) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
- For Diluted EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
- For PBDIT Margin (%), as of Mar 18, the value is 10.56. This value is within the healthy range. It has increased from 1.89 (Mar 17) to 10.56, marking an increase of 8.67.
- For PBIT Margin (%), as of Mar 18, the value is 8.50. This value is below the healthy minimum of 10. It has increased from -1.38 (Mar 17) to 8.50, marking an increase of 9.88.
- For PBT Margin (%), as of Mar 18, the value is 7.67. This value is below the healthy minimum of 10. It has increased from -3.12 (Mar 17) to 7.67, marking an increase of 10.79.
- For Net Profit Margin (%), as of Mar 18, the value is 6.21. This value is within the healthy range. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
- For NP After MI And SOA Margin (%), as of Mar 18, the value is 6.21. This value is below the healthy minimum of 8. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
- For Interest Coverage Ratio (X), as of Mar 18, the value is 10.28. This value is within the healthy range. It has increased from -0.79 (Mar 17) to 10.28, marking an increase of 11.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is 8.50. This value is within the healthy range. It has increased from -1.06 (Mar 17) to 8.50, marking an increase of 9.56.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beryl Drugs Ltd:
- Net Profit Margin: 6.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 50.2 (Industry average Stock P/E: 52.11)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 133, Kanchan Bagh, Indore Madhya Pradesh 452001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Sethi | Chairman & Director |
| Mr. Sanjay Sethi | Managing Director |
| Mr. Abhinav Naik | Independent Director |
| Mrs. Shreya Saraf | Independent Woman Director |
FAQ
What is the intrinsic value of Beryl Drugs Ltd?
Beryl Drugs Ltd's intrinsic value (as of 19 January 2026) is ₹58.81 which is 157.94% higher the current market price of ₹22.80, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹11.5 Cr. market cap, FY2025-2026 high/low of ₹43.0/17.4, reserves of ₹4.37 Cr, and liabilities of ₹17.41 Cr.
What is the Market Cap of Beryl Drugs Ltd?
The Market Cap of Beryl Drugs Ltd is 11.5 Cr..
What is the current Stock Price of Beryl Drugs Ltd as on 19 January 2026?
The current stock price of Beryl Drugs Ltd as on 19 January 2026 is ₹22.8.
What is the High / Low of Beryl Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Beryl Drugs Ltd stocks is ₹43.0/17.4.
What is the Stock P/E of Beryl Drugs Ltd?
The Stock P/E of Beryl Drugs Ltd is 50.2.
What is the Book Value of Beryl Drugs Ltd?
The Book Value of Beryl Drugs Ltd is 18.6.
What is the Dividend Yield of Beryl Drugs Ltd?
The Dividend Yield of Beryl Drugs Ltd is 0.00 %.
What is the ROCE of Beryl Drugs Ltd?
The ROCE of Beryl Drugs Ltd is 10.2 %.
What is the ROE of Beryl Drugs Ltd?
The ROE of Beryl Drugs Ltd is 6.30 %.
What is the Face Value of Beryl Drugs Ltd?
The Face Value of Beryl Drugs Ltd is 10.0.